Ekso Bionics Holdings Inc. Common Stock (EKSO)

FairStock Score: 20/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach a company by asking whether it has a durable competitive advantage and a balance sheet that lets it survive mistakes. Ekso Bionics designs exoskeletons for rehabilitation and mobility, a field with real human need, but the supplied figures show a business still far from proving itself. In the first quarter of fiscal 2026, revenue was $2.1 million while net income was a loss of $6.9 million, producing a net margin of -321.58%. That is not a small shortfall; expenses are more than three times sales. FairStock's calculations show a P/E of -2.31, P/B of 4.65, ROE of -107.62%, ROCE of -33.62%, and debt-to-equity of 0.51. The trailing free cash flow is -$12.1 million, a -31.3% FCF yield against the $38.8 million market cap at the 2026-05-15 close. The supplied growth figures are deeply negative, suggesting the company is shrinking rather than scaling. The Piotroski F-Score of 2/9 and Altman Z-Score of -18.03 indicate weak fundamentals and high financial distress risk. A moat would require pricing power, recurring revenue, or regulatory lock-in; here I see none proven. At $11.80, the market pays 4.65 times book for a money-losing, cash-burning company. That lacks the margin of safety Graham demanded. I would need evidence of durable sales growth and a path to positive cash flow before calling this anything but speculative.

In plain English: Ekso Bionics makes robotic exoskeletons that help people with mobility and rehabilitation. The business looks weak: in the first quarter of fiscal 2026, revenue was $2.1 million and the company lost $6.9 million, and it is burning cash. At the 2026-05-15 price of $11.80, the shares look expensive relative to those weak numbers because the company is not profitable.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-05-15 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer